Phenotypes associated with this allele

• Allele Symbol: Tg(H2-L-IL6)40Csk
• Allele Name: transgene insertion 40, Chugai Pharmaceutical Co Ltd
• Allele ID: MGI:5556099
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cx1	Il6ra^tm1.1(IL6R)Csk/Il6ra^tm1.1(IL6R)Csk Tg(H2-L-IL6)40Csk/0	involves: 129S6/SvEvTac * C57BL/6	MGI:5556112
tg2	Tg(H2-L-IL6)40Csk/0	involves: C57BL/6	MGI:5556113

Genotype
MGI:5556112

cx1

• Allelic Composition: Il6ra^{tm1.1(IL6R)Csk}/Il6ra^{tm1.1(IL6R)Csk}; Tg(H2-L-IL6)40Csk/0
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

enlarged spleen ( J:207264 )

• prior to and after treatment with MR16-1

• however, treatment with tocilizumab prevents development of splenomegaly

increased spleen weight ( J:207264 )

• however, treatment with tocilizumab prevents development of splenomegaly

increased plasma cell number ( J:207264 )

• in the spleen

• however, treatment with ameliorates histological observations

increased spleen white pulp amount ( J:207264 )

• however, treatment with ameliorates histological observations

enlarged lymph nodes ( J:207264 )

hematopoietic system

enlarged spleen ( J:207264 )

• prior to and after treatment with MR16-1

• however, treatment with tocilizumab prevents development of splenomegaly

increased spleen weight ( J:207264 )

• however, treatment with tocilizumab prevents development of splenomegaly

increased plasma cell number ( J:207264 )

• in the spleen

• however, treatment with ameliorates histological observations

increased spleen white pulp amount ( J:207264 )

• however, treatment with ameliorates histological observations

growth/size/body

enlarged spleen ( J:207264 )

• prior to and after treatment with MR16-1

• however, treatment with tocilizumab prevents development of splenomegaly

increased spleen weight ( J:207264 )

• however, treatment with tocilizumab prevents development of splenomegaly

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
lymphoproliferative syndrome		DOID:0060704	OMIM:PS308240	J:207264

Genotype
MGI:5556113

tg2

• Allelic Composition: Tg(H2-L-IL6)40Csk/0
• Genetic Background: involves: C57BL/6

immune system

enlarged spleen ( J:207264 )

• prior to and after tocilizumab treatment

• however, treatment with MR16-1 prevents development of splenomegaly

increased spleen weight ( J:207264 )

• however, treatment with MR16-1 prevents development of splenomegaly

enlarged lymph nodes ( J:207264 )

hematopoietic system

enlarged spleen ( J:207264 )

• prior to and after tocilizumab treatment

• however, treatment with MR16-1 prevents development of splenomegaly

increased spleen weight ( J:207264 )

• however, treatment with MR16-1 prevents development of splenomegaly

growth/size/body

enlarged spleen ( J:207264 )

• prior to and after tocilizumab treatment

• however, treatment with MR16-1 prevents development of splenomegaly

increased spleen weight ( J:207264 )

• however, treatment with MR16-1 prevents development of splenomegaly